SCHEMBL25920563

SCHEMBL25920563

Nc1cc(Nc2cccc(CN3CCCC3)c2)ncn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.51
KDR P35968 2/20 0.50
BRAF P15056 1/20 0.50
MAPK14 Q16539 1/20 0.50
TNNI3K Q59H18 1/20 0.50
JAK2 O60674 1/20 0.44
JAK3 P52333 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
ACP1 P24666 6/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
FGFR3 P22607 1/20 0.42
CYP2C19 P33261 1/20 0.42
PLK4 O00444 1/20 0.41
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12517901 0.79 TNNI3K (0.69) TNNI3K
SCHEMBL4766476 0.77 CYP1A2 (0.53) TNNI3KJAK2JAK3ACP1CYP1A2
SCHEMBL374541 0.77 TNNI3K (0.47) KDRBRAFMAPK14TNNI3KJAK2
SCHEMBL24124990 0.75 BRAF (0.61) KDRBRAFMAPK14TNNI3KCYP1A2
SCHEMBL374636 0.75 CYP2D6 (0.51) TNNI3KALDH1A1ACP1CYP1A2CYP3A4
SCHEMBL374379 0.74 KDM4E (0.46) KDRBRAFMAPK14TNNI3KJAK2
SCHEMBL27318007 0.73 SMN1; SMN2 (0.47) PRMT6JAK2SMN1; SMN2ALDH1A1KDM4E
SCHEMBL11192726 0.72 PRMT6 (0.78) PRMT6SMN1; SMN2ALDH1A1TDP1CYP2C19
SCHEMBL11339852 0.72 PRMT6 (0.78) PRMT6SMN1; SMN2ALDH1A1TDP1CYP2C19
SCHEMBL27319705 0.72 DRD2 (0.44) PRMT6SMN1; SMN2ACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 PRMT6 375/4885KDR 3366/4885BRAF 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.